| scholarly article | Q13442814 |
| P50 | author | Jane A. Cauley | Q19668152 |
| Richard Eastell | Q7325421 | ||
| Ping-Chung Leung | Q87816264 | ||
| Harry K. Genant | Q90560653 | ||
| Christina M Bucci-Rechtweg | Q90946294 | ||
| Douglas C Bauer | Q91116163 | ||
| Dennis M Black | Q92034930 | ||
| Steven Boonen | Q114293114 | ||
| Lisa Palermo | Q114309210 | ||
| Arthur C. Santora | Q114309295 | ||
| Anne E de Papp | Q114407652 | ||
| P2093 | author name string | Michael P Kelly | |
| Fracture Intervention Trial Steering Committee | |||
| HORIZON Pivotal Fracture Trial Steering Committee | |||
| P433 | issue | 19 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | bone fracture | Q68833 |
| P304 | page(s) | 1761-1771 | |
| P577 | publication date | 2010-03-24 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur | |
| P478 | volume | 362 |
| Q38728444 | A Survey of Women's Awareness of and Reasons for Lack of Postfracture Osteoporotic Care |
| Q88417439 | A proposal for an atypical femur fracture treatment and prevention clinical practice guideline |
| Q24594269 | Addition of pamidronate to chemotherapy for the treatment of osteosarcoma |
| Q36199440 | Adult Patients' Perspectives on the Benefits and Harms of Overused Screening Tests: a Qualitative Study. |
| Q37973355 | Adverse drug reactions to osteoporosis treatments |
| Q34189582 | Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis |
| Q37872146 | Aging and osteoporosis in breast and prostate cancer |
| Q92152417 | Antiresorptive-associated spontaneous fractures of both tibiae, followed by an atypical femur fracture during the sequential treatment with alendronate, denosumab then teriparatide |
| Q30870287 | Application of modeling and simulation to a long-term clinical trial: a direct comparison of simulated data and data actually observed in Japanese osteoporosis patients following 3-year ibandronate treatment |
| Q37563703 | Are race and sex associated with the occurrence of atypical femoral fractures? |
| Q36069758 | Are women with thicker cortices in the femoral shaft at higher risk of subtrochanteric/diaphyseal fractures? The study of osteoporotic fractures |
| Q39335004 | Assessment of bone microarchitecture in postmenopausal women on long-term bisphosphonate therapy with atypical fractures of the femur |
| Q33596535 | Association between alendronate and atypical femur fractures: a meta-analysis |
| Q37470866 | Atypical Complete Femoral Fractures Associated with Bisphosphonate Use or Not Associated with Bisphosphonate Use: Is There a Difference? |
| Q33844438 | Atypical femoral fracture after receiving antiresorptive drugs in breast cancer patients with bone metastasis |
| Q33582253 | Atypical femoral fracture risk in patients treated with bisphosphonates |
| Q87420801 | Atypical femoral fractures, bisphosphonates, and mechanical stress |
| Q36016579 | Atypical femoral fractures: epidemiology, etiology, and patient management |
| Q38959195 | Atypical femoral shaft fractures secondary to long-term bisphosphonate therapy |
| Q36059445 | Atypical femur fractures: a review of the evidence and its implication to clinical practice |
| Q35639518 | Atypical fracture of the ulna associated with alendronate use. |
| Q41477033 | Atypical fracture with long-term bisphosphonate therapy is associated with altered cortical composition and reduced fracture resistance. |
| Q40976333 | Atypical fractures, a biased perspective |
| Q36633388 | Atypical subtrochanteric femoral shaft fractures: role for mechanics and bone quality |
| Q36092077 | Atypical subtrochanteric femur fracture in patient with metastatic breast cancer treated with zoledronic Acid |
| Q53656081 | Bilateral atypical femur fractures without bisphosphonate exposure. |
| Q35799470 | Bilateral atypical insufficiency fractures of the proximal tibia and a unilateral distal femoral fracture associated with long-term intravenous bisphosphonate therapy: a case report |
| Q84822917 | Bilateral ulna fractures associated with bisphosphonate therapy |
| Q27004682 | Bisphosphonate drug holiday: choosing appropriate candidates |
| Q36999714 | Bisphosphonate drug holiday: who, when and how long |
| Q38617760 | Bisphosphonate drug holidays--when, why and for how long? |
| Q34305113 | Bisphosphonate treatment and risk of esophageal cancer: a meta-analysis of observational studies |
| Q36493877 | Bisphosphonate treatment of type I diabetic mice prevents early bone loss but accentuates suppression of bone formation |
| Q84643710 | Bisphosphonate use and atypical femur fractures |
| Q38012357 | Bisphosphonate use and increased incidence of subtrochanteric fracture in South Korea: results from the National Claim Registry |
| Q33723995 | Bisphosphonate-induced reductions in rat femoral bone energy absorption and toughness are testing rate-dependent |
| Q42904999 | Bisphosphonates and Atypical Femoral Fractures |
| Q34986933 | Bisphosphonates and atypical fractures of femur |
| Q56969664 | Bisphosphonates and esophageal cancer—a pathway through the confusion |
| Q27026618 | Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project |
| Q37018032 | Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis |
| Q37587913 | Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: sensitivity and trim and fill studies |
| Q36443681 | Bisphosphonates for the treatment of osteoporosis: insights for clinicians |
| Q33715141 | Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays |
| Q37918967 | Bisphosphonates in the treatment of osteoporosis: a review of their contribution and controversies. |
| Q50331318 | Bone Structure and Turnover Status in Postmenopausal Women with Atypical Femur Fracture After Prolonged Bisphosphonate Therapy |
| Q35019051 | Bone disease in HIV infection: a practical review and recommendations for HIV care providers |
| Q38095828 | Bone health and human immunodeficiency virus infection |
| Q83351343 | Can PET-CT imaging and radiokinetic analyses provide useful clinical information on atypical femoral shaft fracture in osteoporotic patients? |
| Q36981973 | Changes in bone resorption across the menopause transition: effects of reproductive hormones, body size, and ethnicity |
| Q35828143 | Changing pattern of femoral fractures in osteogenesis imperfecta with prolonged use of bisphosphonates |
| Q37886780 | Choosing a treatment for patients at the time a fracture is presented |
| Q37058784 | Clinical experience with intravenous zoledronic acid in the treatment of male osteoporosis: evidence and opinions |
| Q36311593 | Clinical role of bisphosphonate therapy |
| Q37862933 | Clinical strategies to address patients' concerns in osteoporosis management with bisphosphonates |
| Q97423995 | Comparative safety and effectiveness of alendronate versus raloxifene in women with osteoporosis |
| Q38294766 | Considerations regarding adherence of anti-osteoporosis therapy. |
| Q37905720 | Contribution of bone tissue modulus to breast cancer metastasis to bone |
| Q34395462 | Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis |
| Q36890431 | Current and emerging therapies for the treatment of osteoporosis |
| Q37843715 | Current and future treatment options in osteoporosis |
| Q34566340 | Current perspectives on bisphosphonate treatment in Paget's disease of bone |
| Q86501823 | Denosumab after 8 years |
| Q24201859 | Denosumab for the treatment and prevention of postmenopausal osteoporosis |
| Q28076646 | Diagnosis and treatment of bone metastasis: comprehensive guideline of the Japanese Society of Medical Oncology, Japanese Orthopedic Association, Japanese Urological Association, and Japanese Society for Radiation Oncology |
| Q35590586 | Diaphyseal femoral fatigue fracture associated with bisphosphonate therapy - 3 more cases |
| Q27021396 | Do bisphosphonates cause femoral insufficiency fractures? |
| Q50623601 | Effect of a single intravenous zoledronic acid administration on biomarkers of acute kidney injury (AKI) in patients with osteoporosis: a pilot study. |
| Q51135820 | Effect of intermittent and daily regimens of minodronic Acid on bone metabolism in an ovariectomized rat model of osteoporosis. |
| Q36109164 | Effect of risedronate on bone in renal transplant recipients |
| Q51764274 | Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density. |
| Q86505152 | Effects of novel cathepsin K inhibitor ONO-5334 on bone resorption markers: a study of four sustained release formulations with different pharmacokinetic patterns |
| Q41704607 | Efficacy, effectiveness and side effects of medications used to prevent fractures. |
| Q84035888 | Fracture prevention in postmenopausal women |
| Q37814414 | Fracture risk associated with chronic use of bisphosphonates: evidence today |
| Q36157622 | Glucocorticoid-induced osteoporosis and osteonecrosis |
| Q37200430 | Glucocorticoids and osteocyte autophagy |
| Q36505624 | Healing of subtrochanteric atypical fractures after strontium ranelate treatment. |
| Q38941307 | Hip fractures in the elderly-: A Clinical Anatomy Review |
| Q36297873 | Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs. |
| Q34707208 | How I treat late effects in adults after allogeneic stem cell transplantation |
| Q36099672 | Hypophosphatasia and the risk of atypical femur fractures: a case-control study |
| Q38248253 | Identifying atypical femoral fractures--a retrospective review |
| Q37792889 | Impact of Treatments for Postmenopausal Osteoporosis (Bisphosphonates, Parathyroid Hormone, Strontium Ranelate, and Denosumab) on Bone Quality: A Systematic Review |
| Q39926515 | Impact of the U.S. Food and Drug Administration's Safety-Related Announcements on the Use of Bisphosphonates After Hip Fracture |
| Q37704201 | Implant failure caused by non-union of bisphosphonate-associated subtrochanteric femur fracture |
| Q33644466 | Improving care after hip fracture: the fracture? Think osteoporosis (FTOP) program |
| Q31026858 | Incidence and Characteristics of Atypical Femoral Fractures: Clinical and Geometrical Data |
| Q50861958 | Incidence and bone biopsy findings of atypical femoral fractures. |
| Q44364497 | Incidence of atypical nontraumatic diaphyseal fractures of the femur |
| Q43694921 | Incidence of serious side effects with intravenous bisphosphonate: a clinical audit |
| Q38407671 | Increased risk for atypical fractures associated with bisphosphonate use. |
| Q34283772 | Is Surgery Necessary for Femoral Insufficiency Fractures after Long-term Bisphosphonate Therapy? |
| Q38186661 | Local strategies to prevent and treat osteoporosis |
| Q34272165 | Long term bisphosphonate therapy & atypical femoral fractures: a word of caution. |
| Q35570961 | Long-term safety concerns of antiresorptive therapy |
| Q35703229 | Longitudinal evaluation of the effects of alendronate on MRI bone microarchitecture in postmenopausal osteopenic women |
| Q36144007 | Low magnitude mechanical signals mitigate osteopenia without compromising longevity in an aged murine model of spontaneous granulosa cell ovarian cancer |
| Q86899636 | Low-energy spontaneous femoral fractures in patients with long-term bisphosphonate therapy |
| Q83144100 | Management of patients with incident fractures during osteoporosis treatment |
| Q37823605 | Managing bone health with zoledronic acid: a review of randomized clinical study results |
| Q35566438 | Mechanical property and tissue mineral density differences among severely suppressed bone turnover (SSBT) patients, osteoporotic patients, and normal subjects |
| Q37807582 | Metabolic bone disease: Atypical femoral fractures |
| Q44804833 | Microindentation for in vivo measurement of bone tissue material properties in atypical femoral fracture patients and controls. |
| Q92966543 | Monostotic Paget's disease of bone - literature review and case report |
| Q57794000 | Myeloma Bone Disease: Update on Pathogenesis and Novel Treatment Strategies |
| Q35036461 | Nonoperative versus prophylactic treatment of bisphosphonate-associated femoral stress fractures |
| Q35578707 | Nutritional and metabolic correlates of cardiovascular and bone disease in HIV-infected patients |
| Q34181008 | Odanacatib, a New Drug for the Treatment of Osteoporosis: Review of the Results in Postmenopausal Women |
| Q37952851 | Optimal management of cancer treatment-induced bone loss: considerations for elderly patients |
| Q35229899 | Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort |
| Q37798836 | Oral salmon calcitonin--pharmacology in osteoporosis |
| Q39625860 | Osteoclast abnormalities in fractured bone during bisphosphonate treatment for osteoporosis: a case report |
| Q38215692 | Osteoporosis and multiple sclerosis: risk factors, pathophysiology, and therapeutic interventions |
| Q30455960 | Osteoporosis imaging: state of the art and advanced imaging |
| Q39255870 | Osteoporosis, bone mineral density and CKD-MBD: treatment considerations. |
| Q30240073 | Osteoporosis: advances in risk assessment and management |
| Q35835844 | Osteoporosis: the emperor has no clothes |
| Q99581904 | Paradoxical Stress Fracture in a Patient With Multiple Myeloma and Bisphosphonate Use |
| Q37945476 | Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw. |
| Q38167678 | Pharmacologic augmentation of implant fixation in osteopenic bone |
| Q91788816 | Pharmacological Therapy of Osteoporosis: What's New? |
| Q33822047 | Physicians' attitudes to contemporary issues on osteoporosis management in Korea |
| Q57543430 | Post-hip fracture use of prescribed calcium plus vitamin D or vitamin D supplements and antiosteoporotic drugs is associated with lower mortality: A nationwide study in Finland |
| Q33818302 | Potential and pitfalls of using large administrative claims data to study the safety of osteoporosis therapies. |
| Q34899110 | Questioning the association between bisphosphonates and atypical femoral fractures |
| Q83730666 | Rapid Onset and Sustained Efficacy (ROSE) study: results of a randomised, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with low bone mass |
| Q26830431 | Rebound effect of modern drugs: serious adverse event unknown by health professionals |
| Q35505244 | Reduced cortical bone compositional heterogeneity with bisphosphonate treatment in postmenopausal women with intertrochanteric and subtrochanteric fractures. |
| Q38187901 | Review: epidemiology and pathophysiology of atypical femur fractures |
| Q36589370 | Risk factors for subtrochanteric and diaphyseal fractures: the study of osteoporotic fractures |
| Q35197628 | Risk of atypical femoral fracture during and after bisphosphonate use. |
| Q34984177 | Role of zoledronic acid in the prevention and treatment of osteoporosis |
| Q37866764 | Safety of long-term bisphosphonate therapy for the management of osteoporosis |
| Q62023153 | Seguridad de los bifosfonatos en el tratamiento de la osteoporosis |
| Q38473594 | Short-term and long-term effects of osteoporosis therapies. |
| Q27010157 | Skeletal complications of bisphosphonate use: what the radiologist should know |
| Q36284335 | Spontaneous Incomplete transverse subtrochanteric femoral fracture with cortical thickening possibly secondary to risedronate use: a case report |
| Q35123288 | Spontaneous subtrochanteric femoral stress fracture related to alendronate : a case report |
| Q36797080 | Subtrochanteric fracture in a patient receiving zoledronic acid therapy for metastatic breast cancer |
| Q34486831 | Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report |
| Q35549448 | Subtrochanteric fractures in bisphosphonate-naive patients: results from the HORIZON-recurrent fracture trial |
| Q51426697 | The 5-year follow-up of a cortical stress fracture resulting in a spontaneous atypical subtrochanteric femoral fracture in a female patient with severe osteoporosis and bisphosphonate therapy over 15 years. |
| Q57145898 | The Challenges and Opportunities of Pharmacoepidemiology in Bone Diseases |
| Q36514299 | The Current and Future Therapies for Human Osteosarcoma |
| Q40077441 | The Effectiveness of Human Parathyroid Hormone and Low-Intensity Pulsed Ultrasound on the Fracture Healing in Osteoporotic Bones |
| Q35756451 | The Time Course Changes in Bone Metabolic Markers after Administering the Anti-Receptor Activator of Nuclear Factor-Kappa B Ligand Antibody and Drug Compliance among Patients with Osteoporosis |
| Q34678657 | The association between serious upper gastrointestinal bleeding and incident bisphosphonate use: a population-based nested cohort study |
| Q44425228 | The correlation between lateral bowing angle of the femur and the location of atypical femur fractures |
| Q36190027 | The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). |
| Q33896122 | The effect of antiresorptives on bone quality |
| Q87928075 | The incidence of and risk factors for developing atypical femoral fractures in Japan |
| Q35584866 | The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future |
| Q38611601 | The safety and tolerability profile of therapies for the prevention and treatment of osteoporosis in postmenopausal women |
| Q35229889 | Trends in Incidence of Subtrochanteric Fragility Fractures and Bisphosphonate Use Among the US Elderly, 1996–2007 |
| Q82589085 | Update in new medications for primary care |
| Q37800181 | Use of bisphosphonates in the management of postmenopausal osteoporosis |
| Q39423898 | Use of bone turnover markers in postmenopausal osteoporosis. |
| Q33770535 | Utility of automated data in identifying femoral shaft and subtrochanteric (diaphyseal) fractures |
| Q33958113 | Validation of diagnostic codes for subtrochanteric, diaphyseal, and atypical femoral fractures using administrative claims data. |
| Q37850819 | Zoledronic acid for prevention and treatment of osteoporosis |
| Q39424272 | Zoledronic acid to prevent and treat cancer metastasis: new prospects for an old drug |
| Q88685550 | [Atypical subtrochanteric femur fracture under alendronate therapy in spite of an intramedullar implant] |
| Q84373473 | [Biphosphonate-induced femoral stress fractures : A new problem and knowledge so far - case report] |
| Q88776195 | [Patient- vs Physician-Reported Implementation of and Compliance to Anti-Osteoporotic Medication One Year after Sustained Fragility Fracture] |
| Q55452474 | Les bisphosphonates dans le traitement de l’ostéoporose: Bienfaits attendus, torts potentiels et congés thérapeutiques. |
Search more.